Fate Therapeutics (FATE) Tops Q3 EPS by 3c

Fate Therapeutics (NASDAQ: FATE) reported Q3 EPS of ($0.86), $0.03 better than the analyst estimate of ($0.89). Revenue for the quarter came in at $14.98 million versus the consensus estimate of $15.71 million.

For earnings history and earnings-related data on Fate Therapeutics (FATE) click here.

You May Also Be Interested In

• Micron offers Taiwan workers up to 68-month bonuses as strike threat looms
• Bernstein SocGen on Oracle (ORCL): 'Next catalyst is FAM'
• DA Davidson Reiterates Buy Rating on Oracle (ORCL) Following Q1 Print